Targeted therapies and immunotherapy for stomach cancer

Targeted therapies interfere with the way cells grow and divide. Immunotherapy uses the immune system to recognise and kill cancer cells.

What are targeted therapies?

Targeted therapy uses drugs to find and attack cancer cells. There are many different types of targeted therapy drugs. Each type targets something in or around the cancer cell that is helping it grow and survive.

Targeted therapy drugs may be used to treat advanced stomach cancer.


Sometimes a targeted therapy drug called trastuzumab is given with chemotherapy to treat advanced stomach cancer.

Trastuzumab only works for people with a stomach cancer that has high levels of a protein called HER2. Between 10 and 15 out of every 100 people with stomach cancer (10 to 15%) have a HER2-positive cancer. Tests can be done on tissue taken at a biopsy or during surgery to find out if the cancer cells have high levels of HER2.

Trastuzumab attaches to the HER2 proteins on the surface of the cancer cells. This stops the cancer cells from dividing and growing.

How trastuzumab is given

Trastuzumab is given as a drip (infusion) every 3 weeks. If it works well, your cancer doctor may decide to keep giving it after your chemotherapy finishes. The side effects of trastuzumab are usually mild.

What is immunotherapy?

Immunotherapy treatments use the immune system to find and attack cancer cells. Some types of immunotherapy are also a targeted therapy.

You may be offered immunotherapy drugs such as nivolumab, or pembrolizumab. These are not widely available through the NHS. When a drug is not available through the NHS, it may still be possible to have it in some situations. Your cancer doctor can tell you more about this. 

Immunotherapy treatment has been shown to be helpful for treating a few different cancers. Currently, immunotherapy is not commonly used to treat stomach cancer. But you may be offered it as part of a clinical trial. Doctors are also testing other targeted therapy drugs in clinical trials.

Date reviewed

Reviewed: 31 December 2019
Next review: 30 June 2022

This content is currently being reviewed. New information will be coming soon.

Trusted Information Creator - Patient Information Forum
Trusted Information Creator - Patient Information Forum

Our cancer information meets the PIF TICK quality mark.

This means it is easy to use, up-to-date and based on the latest evidence. Learn more about how we produce our information.